Literature DB >> 25557289

Epidrug mediated re-expression of miRNA targeting the HMGA transcripts in pituitary cells.

Mark O Kitchen1, Kiren Yacqub-Usman, Richard D Emes, Alan Richardson, Richard N Clayton, William E Farrell.   

Abstract

INTRODUCTION: Transgenic mice overexpressing the high mobility group A (HMGA) genes, Hmga1 or Hmga2 develop pituitary tumours and their overexpression is also a frequent finding in human pituitary adenomas. In some cases, increased expression of HMGA2 but not that of HMGA1 is consequent to genetic perturbations. However, recent studies show that down-regulation of microRNA (miRNA), that contemporaneously target the HMGA1 and HMGA2 transcripts, are associated with their overexpression.
RESULTS: In a cohort of primary pituitary adenoma we determine the impact of epigenetic modifications on the expression of HMGA-targeting miRNA. For these miRNAs, chromatin immunoprecipitations showed that transcript down-regulation is correlated with histone tail modifications associated with condensed silenced genes. The functional impact of epigenetic modification on miRNA expression was determined in the rodent pituitary cell line, GH3. In these cells, histone tail, miRNA-associated, modifications were similar to those apparent in human adenoma and likely account for their repression. Indeed, challenge of GH3 cells with the epidrugs, zebularine and TSA, led to enrichment of the histone modification, H3K9Ac, associated with active genes, and depletion of the modification, H3K27me3, associated with silent genes and re-expression of HMGA-targeting miRNA. Moreover, epidrugs challenges were also associated with a concomitant decrease in hmga1 transcript and protein levels and concurrent increase in bmp-4 expression.
CONCLUSIONS: These findings show that the inverse relationship between HMGA expression and targeting miRNA is reversible through epidrug interventions. In addition to showing a mechanistic link between epigenetic modifications and miRNA expression these findings underscore their potential as therapeutic targets in this and other diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25557289     DOI: 10.1007/s11102-014-0630-5

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  51 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

2.  Epigenomic silencing of the BMP-4 gene in pituitary adenomas: a potential target for epidrug-induced re-expression.

Authors:  Kiren Yacqub-Usman; Cuong V Duong; Richard N Clayton; William E Farrell
Journal:  Endocrinology       Date:  2012-06-14       Impact factor: 4.736

3.  Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway.

Authors:  G Baldassarre; M Fedele; S Battista; A Vecchione; A J Klein-Szanto; M Santoro; T A Waldmann; N Azimi; C M Croce; A Fusco
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

Review 4.  The pituitary tumour epigenome: aberrations and prospects for targeted therapy.

Authors:  Kiren Yacqub-Usman; Alan Richardson; Cuong V Duong; Richard N Clayton; William E Farrell
Journal:  Nat Rev Endocrinol       Date:  2012-04-24       Impact factor: 43.330

5.  Preincubation of pituitary tumor cells with the epidrugs zebularine and trichostatin A are permissive for retinoic acid-augmented expression of the BMP-4 and D2R genes.

Authors:  Kiren Yacqub-Usman; Cuong V Duong; Richard N Clayton; William E Farrell
Journal:  Endocrinology       Date:  2013-03-28       Impact factor: 4.736

Review 6.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues.

Authors:  Heidi J Peltier; Gary J Latham
Journal:  RNA       Date:  2008-03-28       Impact factor: 4.942

Review 8.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

9.  Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data.

Authors:  Chia-Hung Chien; Yi-Ming Sun; Wen-Chi Chang; Pei-Yun Chiang-Hsieh; Tzong-Yi Lee; Wei-Chih Tsai; Jorng-Tzong Horng; Ann-Ping Tsou; Hsien-Da Huang
Journal:  Nucleic Acids Res       Date:  2011-08-05       Impact factor: 16.971

10.  Real-time quantification of microRNAs by stem-loop RT-PCR.

Authors:  Caifu Chen; Dana A Ridzon; Adam J Broomer; Zhaohui Zhou; Danny H Lee; Julie T Nguyen; Maura Barbisin; Nan Lan Xu; Vikram R Mahuvakar; Mark R Andersen; Kai Qin Lao; Kenneth J Livak; Karl J Guegler
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

View more
  8 in total

1.  Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.

Authors:  Mark O Kitchen; Richard T Bryan; Richard D Emes; John R Glossop; Christopher Luscombe; K K Cheng; Maurice P Zeegers; Nicholas D James; Adam J Devall; Charles A Mein; Lyndon Gommersall; Anthony A Fryer; William E Farrell
Journal:  Epigenetics       Date:  2016-03-01       Impact factor: 4.528

2.  Histone Citrullination Represses MicroRNA Expression, Resulting in Increased Oncogene mRNAs in Somatolactotrope Cells.

Authors:  Stanley B DeVore; Coleman H Young; Guangyuan Li; Anitha Sundararajan; Thiruvarangan Ramaraj; Joann Mudge; Faye Schilkey; Aaron Muth; Paul R Thompson; Brian D Cherrington
Journal:  Mol Cell Biol       Date:  2018-09-14       Impact factor: 4.272

Review 3.  High Mobility Group A1 (HMGA1): Structure, Biological Function, and Therapeutic Potential.

Authors:  Lu Wang; Ji Zhang; Min Xia; Chang Liu; Xuyu Zu; Jing Zhong
Journal:  Int J Biol Sci       Date:  2022-07-04       Impact factor: 10.750

4.  Circulating Plasma microRNA to Differentiate Cushing's Disease From Ectopic ACTH Syndrome.

Authors:  Zhanna Belaya; Patimat Khandaeva; Larisa Nonn; Alexey Nikitin; Alexander Solodovnikov; Ivan Sitkin; Andrey Grigoriev; Mikhail Pikunov; Anastasia Lapshina; Liudmila Rozhinskaya; Galina Melnichenko; Ivan Dedov
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-05       Impact factor: 5.555

Review 5.  Non-coding RNA/microRNA-modulatory dietary factors and natural products for improved cancer therapy and prevention: Alkaloids, organosulfur compounds, aliphatic carboxylic acids and water-soluble vitamins.

Authors:  Bernhard Biersack
Journal:  Noncoding RNA Res       Date:  2016-09-03

Review 6.  Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?"

Authors:  Lydia S Lamb; Hao-Wen Sim; Ann I McCormack
Journal:  Cancers (Basel)       Date:  2020-01-28       Impact factor: 6.639

7.  The Role of Aberrant DNA Methylation in Misregulation of Gene Expression in Gonadotroph Nonfunctioning Pituitary Tumors.

Authors:  Paulina Kober; Joanna Boresowicz; Natalia Rusetska; Maria Maksymowicz; Agnieszka Paziewska; Michalina Dąbrowska; Jacek Kunicki; Wiesław Bonicki; Jerzy Ostrowski; Janusz A Siedlecki; Mateusz Bujko
Journal:  Cancers (Basel)       Date:  2019-10-25       Impact factor: 6.639

8.  EZH2 is highly expressed in pituitary adenomas and associated with proliferation.

Authors:  David Schult; Annett Hölsken; Sonja Siegel; Michael Buchfelder; Rudolf Fahlbusch; Ilonka Kreitschmann-Andermahr; Rolf Buslei
Journal:  Sci Rep       Date:  2015-11-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.